|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Enteral stents for the management of malignant colorectal obstruction显示文摘Colorectal cancer(CRC) is the 3rd most common cancer in the United States with more than 10000 new cases diagnosed annually. Approximately 20% of patients with CRC will have distant metastasis at time of diagnosis, making them poor candidates for primary surgical resection. Similarly, 8%-25% of patients with CRC will present with bowel obstruction and will require palliative therapy. Emergent surgical decompression has a high mortality and morbidity, and often leads to a colostomy which impairs the patient's quality of life. In the last decade, there has been an increasing use of colonic stents for palliative therapy to relieve malignant colonic obstruction. Colonic stents have been shown to be effective and safe to treat obstruction from CRC, and are now the therapy of choice in this scenario. In the setting of an acute bowel obstruction in patients with potentially resectable colon cancer, stents may beused to delay surgery and thus allow for decompression, adequate bowel preparation, and optimization of the patient's condition for curative surgical intervention. An overall complication rate(major and minor) of up to 25% has been associated with the procedure. Long term failure of stents may result from stent migration and tumor ingrowth. In the majority of cases, repeat stenting or surgical intervention can successfully overcome these adverse effects. | Jeremy Kaplan Anna Strongin Douglas G Adler Ali A Siddiqui | 2014 | World Journal of Gastroenterology2014，20，37： | 13 |
| 2 | Endoscopic retrograde cholangiopancreatography in cirrhosis-a systematic review and meta-analysis focused on adverse events显示文摘AIM To investigate indications and outcomes of endoscopic retrograde cholangiopancreatography(ERCP) in cirrhotics, especially adverse events. Patients with cirrhosis undergoing ERCP are believed to have increased risk. However, there is a paucity of literature describing the indications and outcomes of ERCP procedures in patients with cirrhosis, especially focusing on adverse events.METHODS We performed a systematic appraisal of major literature databases, including PubMed and EMBASE, with a manual search of literature from their inception until April 2017.RESULTS A total of 6,505 patients from 15 studies were analyzed(male ratio 59%, mean age 59 years), 11% with alcoholic and 89% with non-alcoholic cirrhosis, with 56.2% Child-Pugh class A, and 43.8% class B or C. Indications for ERCP included choledocholithiasis 60.9%, biliary strictures 26.2%, gallstone pancreatitis 21.1% and cholangitis 15.5%. Types of interventions included endoscopic sphincterotomy 52.7%, biliary stenting 16.7% and biliary dilation 4.6%. Individual adverse events included hemorrhage in 4.58%(95%CI: 2.77-6.75%, I^2 = 85.9%), post-ERCP pancreatitis(PEP) in 3.68%(95%CI: 1.83-6.00%, I^2 = 89.5%), cholangitis in 1.93%(95%CI: 0.63-3.71%, I^2 = 87.1%) and perforation in 0.00%(95%CI: 0.00-0.23%, I^2 = 37.8%). Six studies were used for comparison of ERCPrelated complications in cirrhosis vs non-cirrhosis, which showed higher overall rates of complications in cirrhosis patients with pooled OR of 1.63(95%CI: 1.27-2.09, I2 = 65%): higher rates of hemorrhage with OR of 2.05(95%CI: 1.62-2.58, I^2 = 2.1%) and PEP with OR of 1.33(95%CI: 1.04-1.70, I2=65%), but similar cholangitis rates with OR of 1.23(95%CI: 0.67-2.26, I^2 = 44.3%).CONCLUSION There is an overall higher rate of adverse events related to ERCP in patients with cirrhosis, especially hemorrhage and PEP. A thorough risk/benefit assessment should be performed prior to undertaking ERCP in patients with cirrhosis. | Shailender Singh Mashiana Amaninder Singh Dhaliwal Harlan Sayles Banreet Dhindsa Ji Won Yoo Qing Wu shailender singh Ali A Siddiqui Gordon Ohning Mohit Girotra Douglas G Adler | 2018 | World Journal of Gastrointestinal Endoscopy2018，10，11： | 6 |
| 3 | Osteoporosis in men: a review显示文摘Osteoporosis and consequent fracture are not limited to postmenopausal women. There is increasing attention being paid to osteoporosis in older men. Men suffer osteoporotic fractures about 10 years later in life than women, but life expectancy is increasing faster in men than women. Thus, men are living long enough to fracture, and when they do the consequences are greater than in women, with men having about twice the1-year fatality rate after hip fracture, compared to women. Men at high risk for fracture include those men who have already had a fragility fracture, men on oral glucocorticoids or those men being treated for prostate cancer with androgen deprivation therapy. Beyond these high risk men, there are many other risk factors and secondary causes of osteoporosis in men. Evaluation includes careful history and physical examination to reveal potential secondary causes, including many medications, a short list of laboratory tests, and bone mineral density testing by dual energy X-ray absorptiometry(DXA) of spine and hip. Recently, international organizations have advocated a single normative database for interpreting DXA testing in men and women.The consequences of this change need to be determined. There are several choices of therapy for osteoporosis in men, with most fracture reduction estimation based on studies in women. | Robert A Adler | 2014 | Bone Research2014，2，1： | 4 |
| 4 | Neuromuscular electrical stimulation and testosterone did not influence heterotopic ossification size after spinal cor injury: A case series显示文摘Neuromuscular electrical stimulation(NMES) and testosterone replacement therapy(TRT) are effective rehabilitation strategies to attenuate muscle atrophy and evoke hypertrophy in persons with spinal cord injury(SCI). However both interventions might increase heterotopic ossification(HO) size in SCI patients. We present the results of two men with chronic traumatic motor complete SCI who also had pre-existing HO and participated in a study investigating the effects of TRT or TRT plus NMES resistance training(RT) on body composition. The 49-year-old male, Subject A, has unilateral HO in his right thigh. The 31-year-old male, Subject B, has bilateral HO in both thighs. Both participants wore transdermal testosterone patches(4-6 mg/d) daily for 16 wk. Subject A also underwent progressive NMES-RT twice weekly for 16 wk. Magnetic resonance imaging scans were acquired prior to and post intervention. Cross-sectional areas(CSA) of thewhole thigh and knee extensor skeletal muscles, femoral bone, and HO were measured. In Subject A(NMES-RT + TRT), the whole thigh skeletal muscle CSA increased by 10%, the knee extensor CSA increased by 17%, and the HO + femoral bone CSA did not change. In Subject B(TRT), the whole thigh skeletal muscle CSA increased by 13% in the right thigh and 6% in the left thigh. The knee extensor CSA increased by 7% in the right thigh and did not change in the left thigh. The femoral bone and HO CSAs in both thighs did not change. Both the TRT and NMES-RT + TRT protocols evoked muscle hypertrophy without stimulating the growth of preexisting HO. | Pamela D Moore Ashraf S Gorgey Rodney C Wade Refka E Khalil Timothy D Lavis Rehan Khan Robert A Adler | 2016 | World Journal of Clinical Cases2016，4，7： | 3 |
| 5 | Risk of sudden death among young individuals with J waves and early repolarization:putting the evidence into perspective显示文摘 | Rosso R Adler A Halkin A | 2011 | Heart Rhythm2011，，06： | 2 |
| 6 | A reevaluation of the validity of unrestrained plethysmography in mice显示文摘 | Lundblad LK Irvin CG Adler A | 2002 | J Appl Physiol2002，93，4： | 1 |
| 7 | Association of systolic blood pressure with macrovascular and microvascular complications on type 2 diabetes (UKPDS 36 ): prospective observational study 显示文摘 | ADLER A I STRATrON I M NEIL H A | 2000 | BMJ2000，321，： | 1 |
| 8 | UKPDS 59:hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes显示文摘 | Stevens RJ Neil A | 2002 | Diabetes Care2002，25，： | 1 |
| 9 | Association of glycaemia with macrovascular and micro-vascular complications of type 2 diabetes (UKPDS 35): prospective observational study 显示文摘 | Stratton I M Adler A I Neil H A | 2000 | BMJ2000，321，： | 1 |
| 10 | Complexes of deoxyribonucleic acid with lysine-rich (f1) histone phosphorylated at two separate sites:circular dichroism studies显示文摘 | ADLER A J GREENFIELD N FASMAN G D | 1972 | Arch Biochem Biophys1972，153，2： | 1 |
| 11 | Flow in simulated porous media显示文摘 | Adler P M Jacquin C G Quiblier J A | 1990 | International Journal of Multiphase Flow1990，16，： | 1 |
| 12 | Dominance of △5-sterols in eight species of the Caetaceae 显示文摘 | Salt Thomas A Tocker Joel E Adler John H | 1987 | Phytochemistry1987，26，3： | 1 |
| 13 | Cellular automata microsimulation for modeling bi-directional pedestrian walkways显示文摘 | Blue V J Adler J A | 2001 | Transportation Research Part B2001，35，3： | 1 |
| 14 | Persistent and pro- gressive pulmonary fibrotic changes in a model of fat embol- ism显示文摘 | Poisner A M Adler F Uhal B | 2012 | J Trauma Acute Care Surg2012，72，4： | 1 |
| 15 | Prognosis of idiopathic recurrent peri-carditis as determined from previously published reports显示文摘 | Imazio M Brucato A Adler Y Brambilla G Artom G Cecchi E | 2007 | Am J Cardiol2007，100，： | 1 |
| 16 | A primal-dual interior-point framework for using the L1 or L2 norm on the data and regularization terms of inverse problems 显示文摘 | Borsie A Adler A | 2012 | Inverse Problems2012，28，09： | 1 |
| 17 | Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes(UKPDS 35):prospective observational study显示文摘 | Stratton I M Adler A I Neil H A | | 0，，7258： | 1 |
| 18 | UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular dis- ease in type 2 diabetes显示文摘 | Adler AI Stevens R J Neil A | 2002 | Diabetes Care2002，25，： | 1 |
| 19 | Normalization of auditory physiology by cigarette smoking in schizophrenic patients显示文摘 | Adler LE Hoffer LD Wiser A | 1993 | Am J Psychiatry1993，150，： | 1 |
| 20 | Prediotors of the progression of renal disease in the Modification of Diet in Renal Disease Study显示文摘 | Hunsicker LG Adler S Caggiula A | 1997 | Kidney Int1997，51，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员